

## DAFTAR PUSTAKA

- Ahyar, I. R. I. K. A. (2017) 'Regimen Paclitaxel Dan Carboplatin Dengan Regimen Cyclophosphamide, Adriamycin Dan Cisplatin', *Vol. 4 / No. 1 / April 2017/ Jurnal Kesehatan Reproduksi: 1-10*, pp. 1–10.
- Akahira, J. I. *et al.* (2001) 'Prognostic factors of stage IV epithelial ovarian cancer: A multicenter retrospective study', *Gynecologic Oncology*. doi: 10.1006/gyno.2001.6172.
- Asangani, I. A. *et al.* (2008) 'MicroRNA-21 (miR-21) post-transcriptionally downregulates tumor suppressor Pcd4 and stimulates invasion, intravasation and metastasis in colorectal cancer', *Oncogene*. doi: 10.1038/sj.onc.1210856.
- Aukerman, M. J. and Sakai, H. (2003) 'Regulation of Flowering Time and Floral Organ Identity by a MicroRNA and Its APETALA2-Like Target Genes', *Plant Cell*. doi: 10.1105/tpc.016238.
- Aziz, M. F. (2009) 'Gynecological cancer in Indonesia', *Journal of Gynecologic Oncology*, 20(1), pp. 8–10. doi: 10.3802/jgo.2009.20.1.8.
- Bartel, D. P. (2004) 'MicroRNAs: Genomics, Biogenesis, Mechanism, and Function', *Cell*. doi: 10.1016/S0092-8674(04)00045-5.
- Bartlett, T. E. *et al.* (2016) 'Epigenetic reprogramming of fallopian tube fimbriae in BRCA mutation carriers defines early ovarian cancer evolution', *Nature Communications*. doi: 10.1038/ncomms11620.
- Becker, A. *et al.* (2016) 'Extracellular Vesicles in Cancer: Cell-to-Cell Mediators of Metastasis', *Cancer Cell*. doi: 10.1016/j.ccell.2016.10.009.
- Belinga, E. *et al.* (2020) 'Risk factors for ovarian cancer in Yaounde: A case control study', 6, pp. 1–3. doi: 10.15761/COGRM.1000288.
- Beller, U. *et al.* (1983) 'Epithelial carcinoma of the ovary in the reproductive years: Clinical and morphological characterization', *Gynecologic Oncology*. doi: 10.1016/0090-8258(83)90061-6.
- Bhatla, N. and Denny, L. (2018) 'FIGO Cancer Report 2018', *International Journal of Gynecology and Obstetrics*. doi: 10.1002/ijgo.12608.
- Bray, F. *et al.* (2018) 'Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries', *CA: A Cancer Journal for Clinicians*, 68(6), pp. 394–424. doi: 10.3322/caac.21492.
- Brennecke, J. *et al.* (2003) 'bantam encodes a developmentally regulated

microRNA that controls cell proliferation and regulates the proapoptotic gene hid in *Drosophila*’, *Cell*. doi: 10.1016/S0092-8674(03)00231-9.

Buscaglia, L. E. B. and Li, Y. (2011) ‘Apoptosis and the target genes of microRNA-21’, *Chinese Journal of Cancer*. doi: 10.5732/cjc.30.0371.

Buys, S. S. *et al.* (2005) ‘Ovarian cancer screening in the Prostate, Lung, Colorectal and Ovarian (PLCO) cancer screening trial: Findings from the initial screen of a randomized trial’, *American Journal of Obstetrics and Gynecology*, 193(5), pp. 1630–1639. doi: 10.1016/j.ajog.2005.05.005.

Calin, G. A. *et al.* (2002) ‘Frequent deletions and down-regulation of micro-RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia’, *Proceedings of the National Academy of Sciences of the United States of America*. doi: 10.1073/pnas.242606799.

Carey, M. S. *et al.* (2008) ‘The prognostic effects of performance status and quality of life scores on progression-free survival and overall survival in advanced ovarian cancer’, *Gynecologic Oncology*. doi: 10.1016/j.ygyno.2007.08.088.

Chan, J. K. *et al.* (2003) ‘Stages III and IV invasive epithelial ovarian carcinoma in younger versus older women: What prognostic factors are important?’, *Obstetrics and Gynecology*. doi: 10.1016/S0029-7844(03)00399-5.

Chan, J. K. *et al.* (2008) ‘Do clear cell ovarian carcinomas have poorer prognosis compared to other epithelial cell types? A study of 1411 clear cell ovarian cancers’, *Gynecologic Oncology*. doi: 10.1016/j.ygyno.2008.02.006.

Chan, J. K. *et al.* (2014) ‘The inhibition of miR-21 promotes apoptosis and chemosensitivity in ovarian cancer’, *Gynecologic Oncology*. doi: 10.1016/j.ygyno.2014.01.034.

Chang, L. C. *et al.* (2018) ‘Prognostic factors in epithelial ovarian cancer: A population-based study’, *PLoS ONE*. doi: 10.1371/journal.pone.0194993.

Chen, C. Z. *et al.* (2004) ‘MicroRNAs Modulate Hematopoietic Lineage Differentiation’, *Science*. doi: 10.1126/science.1091903.

Chen, S. N. *et al.* (2019) ‘MicroRNA in ovarian cancer: Biology, pathogenesis, and therapeutic opportunities’, *International Journal of Environmental Research and Public Health*, 16(9), pp. 1–14. doi: 10.3390/ijerph16091510.

Chen, X. (2004) ‘A MicroRNA as a Translational Repressor of APETALA2 in Arabidopsis Flower Development’, *Science*. doi: 10.1126/science.1088060.

Cheng, A. M. *et al.* (2005) ‘Antisense inhibition of human miRNAs and indications for an involvement of miRNA in cell growth and apoptosis’, *Nucleic Acids Research*. doi: 10.1093/nar/gki200.

- Chiang, Y. C. *et al.* (2013) 'Trends in incidence and survival outcome of epithelial ovarian cancer: 30-year national population-based registry in Taiwan', *Journal of Gynecologic Oncology*. doi: 10.3802/jgo.2013.24.4.342.
- Cmarik, J. L. *et al.* (1999) 'Differentially expressed protein Pcd4 inhibits tumor promoter-induced neoplastic transformation', *Proceedings of the National Academy of Sciences of the United States of America*. doi: 10.1073/pnas.96.24.14037.
- Cochrane, D. R. *et al.* (2009) 'MicroRNA-200c mitigates invasiveness and restores sensitivity to microtubule-targeting chemotherapeutic agents', *Molecular Cancer Therapeutics*. doi: 10.1158/1535-7163.MCT-08-1046.
- Corsten, M. F. *et al.* (2010) 'Circulating MicroRNA-208b and MicroRNA-499 reflect myocardial damage in cardiovascular disease', *Circulation: Cardiovascular Genetics*. doi: 10.1161/CIRCGENETICS.110.957415.
- Damayanti, I. N., Yulianti, I. and Kusumastuti, E. H. (2018) 'Three years survival rate of epithelial ovarian cancer patients in Dr. Kariadi Hospital, Semarang, Central Java', *Majalah Obstetri & Ginekologi*, 24(3), p. 100. doi: 10.20473/mog.v24i32016.100-104.
- Davis, B. N. *et al.* (2010) 'Smad proteins bind a conserved RNA sequence to promote MicroRNA maturation by Drosha', *Molecular Cell*. doi: 10.1016/j.molcel.2010.07.011.
- Desjardins, P. and Conklin, D. (2010) 'NanoDrop microvolume quantitation of nucleic acids', *Journal of Visualized Experiments*. doi: 10.3791/2565.
- Dillhoff, M. *et al.* (2008) 'MicroRNA-21 is overexpressed in pancreatic cancer and a potential predictor of survival', *Journal of Gastrointestinal Surgery*. doi: 10.1007/s11605-008-0584-x.
- Dvinge, H. *et al.* (2013) 'The shaping and functional consequences of the microRNA landscape in breast cancer', *Nature*. doi: 10.1038/nature12108.
- Egidi, M. G. *et al.* (2013) 'Circulating microRNAs and Kallikreins before and after radical prostatectomy: Are they really prostate cancer markers?', *BioMed Research International*, 2013. doi: 10.1155/2013/241780.
- Eisenkop, S. M., Friedman, R. L. and Wang, H. J. (1998) 'Complete cytoreductive surgery is feasible and maximizes survival in patients with advanced epithelial ovarian cancer: A prospective study', *Gynecologic Oncology*. doi: 10.1006/gyno.1998.4955.
- Feinberg, A. P. and Tycko, B. (2004) 'The history of cancer epigenetics', *Nature Reviews Cancer*. doi: 10.1038/nrc1279.

- Gallo, A. *et al.* (2012) 'The majority of microRNAs detectable in serum and saliva is concentrated in exosomes', *PLoS ONE*. doi: 10.1371/journal.pone.0030679.
- Gao, Y. chun and Wu, J. (2015) 'MicroRNA-200c and microRNA-141 as potential diagnostic and prognostic biomarkers for ovarian cancer', *Tumor Biology*. doi: 10.1007/s13277-015-3138-3.
- Grasedieck, S. *et al.* (2012) 'Impact of serum storage conditions on microRNA stability', *Leukemia*, 26(11), pp. 2414–2416. doi: 10.1038/leu.2012.106.
- Griffiths-Jones, S. *et al.* (2008) 'miRBase: Tools for microRNA genomics', *Nucleic Acids Research*, 36(SUPPL. 1), pp. 154–158. doi: 10.1093/nar/gkm952.
- Gronlund, B. *et al.* (2002) 'Performance status rather than age is the key prognostic factor in second-line treatment of elderly patients with epithelial ovarian carcinoma', *Cancer*. doi: 10.1002/cncr.10385.
- Gupta, D. *et al.* (2010) 'Impact of improved nutritional status on survival in ovarian cancer', *Supportive Care in Cancer*. doi: 10.1007/s00520-009-0670-y.
- Ha, M. and Kim, V. N. (2014) 'Regulation of microRNA biogenesis', *Nature Reviews Molecular Cell Biology*. doi: 10.1038/nrm3838.
- Hanahan, D. and Weinberg, R. A. (2011) 'Hallmarks of cancer: The next generation', *Cell*. doi: 10.1016/j.cell.2011.02.013.
- Hatfield, S. D. *et al.* (2005) 'Stem cell division is regulated by the microRNA pathway', *Nature*. doi: 10.1038/nature03816.
- Hayes, J., Peruzzi, P. P. and Lawler, S. (2014) 'MicroRNAs in cancer: Biomarkers, functions and therapy', *Trends in Molecular Medicine*. doi: 10.1016/j.molmed.2014.06.005.
- Hoskins, W. J. *et al.* (1992) 'The influence of cytoreductive surgery on recurrence-free interval and survival in small-volume Stage III epithelial ovarian cancer: A gynecologic oncology group study', *Gynecologic Oncology*. doi: 10.1016/0090-8258(92)90100-W.
- Houbaviy, H. B., Murray, M. F. and Sharp, P. A. (2003) 'Embryonic stem cell-specific microRNAs', *Developmental Cell*. doi: 10.1016/S1534-5807(03)00227-2.
- Hsu, C. M. *et al.* (2012) 'Circulating miRNA is a novel marker for head and neck squamous cell carcinoma.', *Tumour biology: the journal of the International Society for Oncodevelopmental Biology and Medicine*. doi: 10.1007/s13277-012-0454-8.

- Hu, X. *et al.* (2009) 'A miR-200 microRNA cluster as prognostic marker in advanced ovarian cancer', *Gynecologic Oncology*. doi: 10.1016/j.ygyno.2009.05.022.
- Iorio, M. V. *et al.* (2005) 'MicroRNA gene expression deregulation in human breast cancer', *Cancer Research*. doi: 10.1158/0008-5472.CAN-05-1783.
- Iorio, M. V. *et al.* (2007) 'MicroRNA signatures in human ovarian cancer', *Cancer Research*, 67(18), pp. 8699–8707. doi: 10.1158/0008-5472.CAN-07-1936.
- Jansen, A. P., Camalier, C. E. and Colburn, N. H. (2005) 'Epidermal expression of the translation inhibitor programmed cell death 4 suppresses tumorigenesis', *Cancer Research*. doi: 10.1158/0008-5472.CAN-04-2119.
- Jin, B., Li, Y. and Robertson, K. D. (2011) 'DNA methylation: Superior or subordinate in the epigenetic hierarchy?', *Genes and Cancer*. doi: 10.1177/1947601910393957.
- Johnston, R. J. and Hobert, O. (2003) 'A microRNA controlling left/right neuronal asymmetry in *Caenorhabditis elegans*', *Nature*. doi: 10.1038/nature02255.
- Kalluri, R. and LeBleu, V. S. (2020) 'The biology, function, and biomedical applications of exosomes', *Science*. doi: 10.1126/science.aau6977.
- Kasinski, A. L. and Slack, F. J. (2011) 'MicroRNAs en route to the clinic: Progress in validating and targeting microRNAs for cancer therapy', *Nature Reviews Cancer*. Nature Publishing Group, 11(12), pp. 849–864. doi: 10.1038/nrc3166.
- Kim, V. N. (2005) 'MicroRNA biogenesis: Coordinated cropping and dicing', *Nature Reviews Molecular Cell Biology*. doi: 10.1038/nrm1644.
- Konishi, H. *et al.* (2012) 'Detection of gastric cancer-associated microRNAs on microRNA microarray comparing pre- and post-operative plasma', *British Journal of Cancer*. doi: 10.1038/bjc.2011.588.
- Kotsopoulos, J. *et al.* (2018) 'Age-specific ovarian cancer risks among women with a BRCA1 or BRCA2 mutation', *Gynecologic Oncology*. Elsevier Inc., 150(1), pp. 85–91. doi: 10.1016/j.ygyno.2018.05.011.
- Kozera, B. and Rapacz, M. (2013) 'Reference genes in real-time PCR', *Journal of Applied Genetics*. doi: 10.1007/s13353-013-0173-x.
- Krol, J., Loedige, I. and Filipowicz, W. (2010) 'The widespread regulation of microRNA biogenesis, function and decay', *Nature Reviews Genetics*. doi: 10.1038/nrg2843.
- Kurman, R. J. and Shih, I. M. (2016) 'The dualistic model of ovarian carcinogenesis

- revisited, revised, and expanded', *American Journal of Pathology*. doi: 10.1016/j.ajpath.2015.11.011.
- Lagos-Quintana, M. *et al.* (2001) 'Identification of novel genes coding for small expressed RNAs', *Science*. doi: 10.1126/science.1064921.
- Lange, T. *et al.* (2017) 'Identification of miR-16 as an endogenous reference gene for the normalization of urinary exosomal miRNA expression data from CKD patients', *PLoS ONE*, 12(8), pp. 1–13. doi: 10.1371/journal.pone.0183435.
- Larrea, E. *et al.* (2016) 'New concepts in cancer biomarkers: Circulating miRNAs in liquid biopsies', *International Journal of Molecular Sciences*. doi: 10.3390/ijms17050627.
- Laterza, O. F. *et al.* (2009) 'Plasma microRNAs as sensitive and specific biomarkers of tissue injury', *Clinical Chemistry*. doi: 10.1373/clinchem.2009.131797.
- Lau, N. C. *et al.* (2001) 'An abundant class of tiny RNAs with probable regulatory roles in *Caenorhabditis elegans*', *Science*. doi: 10.1126/science.1065062.
- Le, H. B. *et al.* (2012) 'Evaluation of dynamic change of serum miR-21 and miR-24 in pre- and post-operative lung carcinoma patients', *Medical Oncology*. doi: 10.1007/s12032-012-0303-z.
- Lee, R. C., Feinbaum, R. L. and Ambros, V. (1993) 'The *C. elegans* heterochronic gene *lin-4* encodes small RNAs with antisense complementarity to *lin-14*', *Cell*. doi: 10.1016/0092-8674(93)90529-Y.
- Lengyel, E. (2010) 'Ovarian cancer development and metastasis', *American Journal of Pathology*. doi: 10.2353/ajpath.2010.100105.
- Li, K. *et al.* (2019) 'Exosomes play roles in sequential processes of tumor metastasis', *International Journal of Cancer*. doi: 10.1002/ijc.31774.
- Livak, K. J. and Schmittgen, T. D. (2001) 'Analysis of relative gene expression data using real-time quantitative PCR and the 2- $\Delta\Delta$ CT method', *Methods*, 25(4), pp. 402–408. doi: 10.1006/meth.2001.1262.
- Loginov, V. I. *et al.* (2018) 'Novel miRNA genes deregulated by aberrant methylation in ovarian carcinoma are involved in metastasis', *Gene*. doi: 10.1016/j.gene.2018.04.005.
- Lou (2010) 'MicroRNA-21 promotes the cell proliferation, invasion and migration abilities in ovarian epithelial carcinomas through inhibiting the expression of PTEN protein', *International Journal of Molecular Medicine*. doi: 10.3892/ijmm\_00000530.

- Lu, J. *et al.* (2005) 'MicroRNA expression profiles classify human cancers', *Nature*. doi: 10.1038/nature03702.
- Lucidi, A. *et al.* (2020) 'Role of extracellular vesicles in epithelial ovarian cancer: A systematic review', *International Journal of Molecular Sciences*. doi: 10.3390/ijms21228762.
- Ludwig, K. *et al.* (2013) 'PDCD4/miR-21 dysregulation in inflammatory bowel disease-associated carcinogenesis', *Virchows Archiv*. doi: 10.1007/s00428-012-1345-5.
- Ma, G. J. *et al.* (2013) 'Plasma post-operative miR-21 expression in the prognosis of gastric cancers', *Asian Pacific Journal of Cancer Prevention*. doi: 10.7314/APJCP.2013.14.12.7551.
- Mahmood, N. *et al.* (2019) 'Circulating miR-21 as a prognostic and predictive biomarker in oral squamous cell carcinoma', *Pakistan Journal of Medical Sciences*. doi: 10.12669/pjms.35.5.331.
- Mahmoud, E. H., Fawzy, A. and Elshimy, R. A. A. (2018) 'Serum microRNA-21 negatively relates to expression of programmed cell death-4 in patients with Epithelial ovarian cancer', *Asian Pacific Journal of Cancer Prevention*, 19(1), pp. 33–38. doi: 10.22034/APJCP.2018.19.1.33.
- Markman, M. *et al.* (1993) 'Impact of Age on Survival of Patients with Ovarian Cancer', *Gynecologic Oncology*, 49(2), pp. 236–239. doi: 10.1006/gyno.1993.1113.
- Markou, A. *et al.* (2008) 'Prognostic value of mature MicroRNA-21 and MicroRNA-205 overexpression in non-small cell lung cancer by quantitative real-time RT-PCR', *Clinical Chemistry*. doi: 10.1373/clinchem.2007.101741.
- Massi, D. *et al.* (1996) 'Epithelial ovarian tumors in the reproductive: Age group age is not an independent prognostic factor', *Cancer*. doi: 10.1002/(SICI)1097-0142(19960315)77:6<1131::AID-CNCR19>3.0.CO;2-2.
- Matias-Garcia, P. R. *et al.* (2020) 'Impact of long-term storage and freeze-thawing on eight circulating microRNAs in plasma samples', *PLoS ONE*. doi: 10.1371/journal.pone.0227648.
- Meisgen, F. *et al.* (2012) 'miR-21 is up-regulated in psoriasis and suppresses T cell apoptosis', *Experimental Dermatology*. doi: 10.1111/j.1600-0625.2012.01462.x.
- Meltzer, P. S. (2005) 'Small RNAs with big impacts', *Nature*. doi: 10.1038/435745a.

- Meng, F. *et al.* (2007) 'MicroRNA-21 Regulates Expression of the PTEN Tumor Suppressor Gene in Human Hepatocellular Cancer', *Gastroenterology*. doi: 10.1053/j.gastro.2007.05.022.
- Mitchell, P. S. *et al.* (2008) 'Circulating microRNAs as stable blood-based markers for cancer detection', *Proceedings of the National Academy of Sciences of the United States of America*. doi: 10.1073/pnas.0804549105.
- Momenimovahed, Z. *et al.* (2019) 'Ovarian cancer in the world: Epidemiology and risk factors', *International Journal of Women's Health*. doi: 10.2147/IJWH.S197604.
- Naito, Y. *et al.* (2017) 'How cancer cells dictate their microenvironment: present roles of extracellular vesicles', *Cellular and Molecular Life Sciences*. doi: 10.1007/s00018-016-2346-3.
- Nakamura, K. *et al.* (2019) 'Role of the exosome in ovarian cancer progression and its potential as a therapeutic target', *Cancers*. doi: 10.3390/cancers11081147.
- Nam, E. J. *et al.* (2008) 'MicroRNA expression profiles in serous ovarian carcinoma', *Clinical Cancer Research*. doi: 10.1158/1078-0432.CCR-07-1731.
- Noela, F. and Nuryanto, K. H. (2016) 'Epidemiology Data of Ovarian Cancer in Dr. Cipto Mangunkusumo Hospital, Jakarta', *Indonesian Journal of Obstetrics and Gynecology*. doi: 10.32771/inajog.v4i2.84.
- Nolan, T. and Bustin, S. (2010) 'Chapter 9. Procedures for Quality Control of RNA Samples for Use in Quantitative Reverse Transcription PCR', *Essentials of Nucleic Acid Analysis*, pp. 189–207. doi: 10.1039/9781847558213-00189.
- Oken, M. M. . M. D. *et al.* (1982) 'Toxicity and response criteria of the Eastern Cooperative On... : American Journal of Clinical Oncology', *American Journal of Clinical Oncology*.
- Ørskov, M. *et al.* (2016) 'Predictors of mortality within 1 year after primary ovarian cancer surgery: A nationwide cohort study', *BMJ Open*. doi: 10.1136/bmjopen-2015-010123.
- Palatnik, J. F. *et al.* (2003) 'Control of leaf morphogenesis by microRNAs', *Nature*. doi: 10.1038/nature01958.
- Peacock, O. *et al.* (2014) 'Inflammation and MiR-21 pathways functionally interact to downregulate PDCD4 in colorectal cancer', *PLoS ONE*. doi: 10.1371/journal.pone.0110267.
- Peinado, H., Lavotshkin, S. and Lyden, D. (2011) 'The secreted factors responsible

- for pre-metastatic niche formation: Old sayings and new thoughts', *Seminars in Cancer Biology*. doi: 10.1016/j.semcancer.2011.01.002.
- Potts, M. (2008) 'Atlas of Contraception 2nd edition', *Journal of Obstetrics & Gynecology*, 28(6), p. 665. doi: 10.1080/01443610802397710.
- Prat, J. (2012) 'Ovarian carcinomas: Five distinct diseases with different origins, genetic alterations, and clinicopathological features', *Virchows Archiv*. doi: 10.1007/s00428-012-1203-5.
- Ratajczak, J. *et al.* (2006) 'Membrane-derived microvesicles: Important and underappreciated mediators of cell-to-cell communication', *Leukemia*. doi: 10.1038/sj.leu.2404296.
- Reinhart, B. J. *et al.* (2000) 'The 21-nucleotide let-7 RNA regulates developmental timing in *Caenorhabditis elegans*', *Nature*. doi: 10.1038/35002607.
- Resnick, K. E. *et al.* (2009) 'The detection of differentially expressed microRNAs from the serum of ovarian cancer patients using a novel real-time PCR platform', *Gynecologic Oncology*. doi: 10.1016/j.ygyno.2008.08.036.
- Schetter, A. J. *et al.* (2008) 'MicroRNA expression profiles associated with prognosis and therapeutic outcome in colon adenocarcinoma', *JAMA - Journal of the American Medical Association*. doi: 10.1001/jama.299.4.425.
- Schnack, T. H. *et al.* (2016) 'Demographic Clinical and Prognostic Factors of Primary Ovarian Adenocarcinomas of Serous and Clear Cell Histology-A Comparative Study', in *International Journal of Gynecological Cancer*. doi: 10.1097/IGC.0000000000000585.
- Sethupathy, P., Corda, B. and Hatzigeorgiou, A. G. (2006) 'TarBase: A comprehensive database of experimentally supported animal microRNA targets', *RNA*. doi: 10.1261/rna.2239606.
- Sharma, S., Kelly, T. K. and Jones, P. A. (2009) 'Epigenetics in cancer', *Carcinogenesis*. doi: 10.1093/carcin/bgp220.
- Shen, L. *et al.* (2015) 'The clinical utility of microRNA-21 as novel biomarker for diagnosing human cancers', *Tumor Biology*. doi: 10.1007/s13277-014-2806-z.
- Shih, I. M. and Kurman, R. J. (2004) 'Ovarian Tumorigenesis: A Proposed Model Based on Morphological and Molecular Genetic Analysis', *American Journal of Pathology*. doi: 10.1016/S0002-9440(10)63708-X.
- Sihombing Marice, S. A. M. (2010) 'Angka Ketahanan Hidup Penderita Kanker Ovarium di RS Dr. Cipto Mangunkusumo Jakarta', *Maj Kedokt Indon*, V, 57(10), pp. 348–370.

- Singh, A., Gupta, S. and Sachan, M. (2019) 'Epigenetic biomarkers in the management of ovarian cancer: Current perspectives', *Frontiers in Cell and Developmental Biology*. doi: 10.3389/fcell.2019.00182.
- Song, J. *et al.* (2012) 'Identification of suitable reference genes for qPCR analysis of serum microRNA in gastric cancer patients', *Digestive Diseases and Sciences*, 57(4), pp. 897–904. doi: 10.1007/s10620-011-1981-7.
- Sorrentino, A. *et al.* (2008) 'Role of microRNAs in drug-resistant ovarian cancer cells', *Gynecologic Oncology*. doi: 10.1016/j.ygyno.2008.08.017.
- Sourvinou, I. S., Markou, A. and Lianidou, E. S. (2013) 'Quantification of circulating miRNAs in plasma: Effect of preanalytical and analytical parameters on their isolation and stability', *Journal of Molecular Diagnostics*. doi: 10.1016/j.jmoldx.2013.07.005.
- Stahlhut, C. and Slack, F. J. (2013) 'MicroRNAs and the cancer phenotype: profiling, signatures and clinical implications', *Genome Medicine*. doi: 10.1186/gm516.
- Sullivan, R. *et al.* (2017) 'The emerging roles of extracellular vesicles as communication vehicles within the tumor microenvironment and beyond', *Frontiers in Endocrinology*. doi: 10.3389/fendo.2017.00194.
- T., T. *et al.* (2009) 'Effect of MDR1 gene promoter methylation in patients with ulcerative colitis', *International Journal of Molecular Medicine*, 23(4), pp. 521–527. doi: 10.3892/ijmm.
- Tao, S. C. and Guo, S. C. (2020) 'Role of extracellular vesicles in tumour microenvironment', *Cell Communication and Signaling*. Cell Communication and Signaling, 18(1), pp. 1–24. doi: 10.1186/s12964-020-00643-5.
- Taylor, D. D. and Gercel-Taylor, C. (2008) 'MicroRNA signatures of tumor-derived exosomes as diagnostic biomarkers of ovarian cancer', *Gynecologic Oncology*. doi: 10.1016/j.ygyno.2008.04.033.
- Tewari, D. *et al.* (2015) 'Long-term survival advantage and prognostic factors associated with intraperitoneal chemotherapy treatment in advanced ovarian cancer: A gynecologic oncology group study', *Journal of Clinical Oncology*. doi: 10.1200/JCO.2014.55.9898.
- The World Ovarian Cancer Coalition (2018) 'The World Ovarian Cancer Coalition Atlas: Global Trends in Incidence, Mortality and Survival', *The every woman study*, (April), pp. 1–39.
- Toiyama, Y. *et al.* (2013) 'Serum miR-21 as a diagnostic and prognostic biomarker in colorectal cancer.', *Journal of the National Cancer Institute*. doi:

10.1093/jnci/djt101.

Trihandini, I. and Nurrika, D. (2007) 'Ovarium Epithelial di Rumah Sakit Kanker Dharmais Jakarta Five-Year Survival Analysis of Epithelial Ovarian Cancer Patients of Dharmais Cancer Hospital Jakarta', *Jurnal Kesehatan Masyarakat Nasional*, 5, pp. 139–144.

Trillsch, F. *et al.* (2013) 'Treatment reality in elderly patients with advanced ovarian cancer: A prospective analysis of the OVCAD consortium', *Journal of Ovarian Research*. doi: 10.1186/1757-2215-6-42.

Trirahmanto, A. (2018) 'EKSPRESI miR-21, mRNA PDCD4, miR-200c, dan mRNA TUBB3 PLASMA SEBAGAI FAKTOR PROGNOSIS KANKER OVARIUM EPITEL', *Universitas Gadjah Mada*.

Trirahmanto, A. *et al.* (2019) 'The role of circulating MicroRNA-21 (miR-21) in epithelial ovarian cancer', *Bali Medical Journal*, 8(1), p. 128. doi: 10.15562/bmj.v8i1.1323.

Turchinovich, A. *et al.* (2011) 'Characterization of extracellular circulating microRNA', *Nucleic Acids Research*. doi: 10.1093/nar/gkr254.

Vilming Elgaaen, B. *et al.* (2014) 'Global miRNA expression analysis of serous and clear cell ovarian carcinomas identifies differentially expressed miRNAs including miR-200c-3p as a prognostic marker', *BMC Cancer*. doi: 10.1186/1471-2407-14-80.

Voest, E. E., van Houtwelingen, J. C. and Neijt, J. P. (1989) 'A meta-analysis of prognostic factors in advanced ovarian cancer with median survival and overall survival (measured with the log (relative risk)) as main objectives', *European Journal of Cancer and Clinical Oncology*. doi: 10.1016/0277-5379(89)90208-3.

Volinia, S. *et al.* (2006) 'A microRNA expression signature of human solid tumors defines cancer gene targets', *Proceedings of the National Academy of Sciences of the United States of America*. doi: 10.1073/pnas.0510565103.

Wagey, I. T. G. M. F. L. F. W. (2016) 'Gambaran jenis kanker ovarium di RSUP Prof. Dr. R. D. Kandou Manado', *E-Clinic*, 4, pp. 2–6.

Wang, B. and Zhang, Q. (2012) 'The expression and clinical significance of circulating microRNA-21 in serum of five solid tumors', *Journal of Cancer Research and Clinical Oncology*. doi: 10.1007/s00432-012-1244-9.

Wang, F. *et al.* (2010) 'Correlation and quantitation of microRNA aberrant expression in tissues and sera from patients with breast tumor', *Gynecologic Oncology*. doi: 10.1016/j.ygyno.2010.07.021.

- Wang, K. and Li, P. F. (2010) 'Foxo3a regulates apoptosis by negatively targeting miR-21', *Journal of Biological Chemistry*. doi: 10.1074/jbc.M109.093005.
- Wang, T. *et al.* (2012) 'MiR-21 regulates skin wound healing by targeting multiple aspects of the healing process', *American Journal of Pathology*. doi: 10.1016/j.ajpath.2012.08.022.
- Wang, Y. *et al.* (2014) 'Diagnostic and prognostic value of circulating miR-21 for cancer: A systematic review and meta-analysis', *Gene*. doi: 10.1016/j.gene.2013.09.038.
- Wang, Y. *et al.* (2015) 'Prediction of poor prognosis in breast cancer patients based on MicroRNA-21 expression: A meta-analysis', *PLoS ONE*. doi: 10.1371/journal.pone.0118647.
- Wang, Z. X. *et al.* (2011) 'Prognostic significance of serum miRNA-21 expression in human non-small cell lung cancer', *Journal of Surgical Oncology*. doi: 10.1002/jso.22008.
- Wei, W. *et al.* (2017) 'Clinical outcome and prognostic factors of patients with earlystage epithelial ovarian cancer', *Oncotarget*. doi: 10.18632/oncotarget.13317.
- Winter, W. E. *et al.* (2007) 'Prognostic factors for stage III epithelial ovarian cancer: A Gynecologic Oncology Group study', *Journal of Clinical Oncology*, 25(24), pp. 3621–3627. doi: 10.1200/JCO.2006.10.2517.
- Xiong, B. *et al.* (2013) 'MiR-21 regulates biological behavior through the PTEN/PI-3 K/Akt signaling pathway in human colorectal cancer cells', *International Journal of Oncology*. doi: 10.3892/ijo.2012.1707.
- Xiong, X. *et al.* (2018) 'Fbp1 promotes ovarian cancer development through the acceleration of cell cycle transition and metastasis', *Oncology Letters*. doi: 10.3892/ol.2018.8872.
- Xu, P. *et al.* (2003) 'The Drosophila microRNA mir-14 suppresses cell death and is required for normal fat metabolism', *Current Biology*. doi: 10.1016/S0960-9822(03)00250-1.
- Xu, Y. Z. *et al.* (2013) 'Identification of serum microRNA-21 as a biomarker for early detection and prognosis in human epithelial ovarian cancer', *Asian Pacific Journal of Cancer Prevention*, 14(2), pp. 1057–1060. doi: 10.7314/APJCP.2013.14.2.1057.
- Yang, C. H. *et al.* (2011) 'MicroRNA miR-21 regulates the metastatic behavior of B16 melanoma cells', *Journal of Biological Chemistry*. doi: 10.1074/jbc.M111.285098.

- Yang, C. H. *et al.* (2015) 'The oncogenic microRNA-21 inhibits the tumor suppressive activity of FBXO11 to promote tumorigenesis', *Journal of Biological Chemistry*. doi: 10.1074/jbc.M114.632125.
- Yang, H. *et al.* (2008) 'MicroRNA expression profiling in human ovarian cancer: miR-214 induces cell survival and cisplatin resistance by targeting PTEN', *Cancer Research*. doi: 10.1158/0008-5472.CAN-07-2488.
- Yang, Q. *et al.* (2014) 'Evaluation and validation of the suitable control genes for quantitative PCR studies in plasma DNA for non-invasive prenatal diagnosis', *International Journal of Molecular Medicine*. doi: 10.3892/ijmm.2014.1944.
- Yoshikawa, K. *et al.* (2018) 'Age-related differences in prognosis and prognostic factors among patients with epithelial ovarian cancer', *Molecular and Clinical Oncology*. doi: 10.3892/mco.2018.1668.
- Zhang, B. *et al.* (2007) 'microRNAs as oncogenes and tumor suppressors', *Developmental Biology*, 302(1), pp. 1–12. doi: 10.1016/j.ydbio.2006.08.028.
- Zhang, H., Xu, S. and Liu, X. (2019) 'MicroRNA profiling of plasma exosomes from patients with ovarian cancer using high-throughput sequencing', *Oncology Letters*. doi: 10.3892/ol.2019.10220.
- Zhao, H. *et al.* (2016) 'Tumor microenvironment derived exosomes pleiotropically modulate cancer cell metabolism', *eLife*. doi: 10.7554/eLife.10250.
- Zhou, W. *et al.* (2018) 'MicroRNA-21 down-regulates inflammation and inhibits periodontitis', *Molecular Immunology*, 101(January), pp. 608–614. doi: 10.1016/j.molimm.2018.05.008.
- Zhu, S. *et al.* (2007) 'MicroRNA-21 targets the tumor suppressor gene tropomyosin 1 (TPM1)', *Journal of Biological Chemistry*. doi: 10.1074/jbc.M611393200.
- Zhu, T. *et al.* (2017) 'A Pilot Study of Circulating MicroRNA-125b as a Diagnostic and Prognostic Biomarker for Epithelial Ovarian Cancer', *International Journal of Gynecological Cancer*. doi: 10.1097/IGC.0000000000000846.
- Zhu, W. and Xu, B. (2014) 'MicroRNA-21 identified as predictor of cancer outcome: A meta-analysis', *PLoS ONE*. doi: 10.1371/journal.pone.0103373.